Retevmo (Selpercatinib) Patent Expiration, LOE Window & CMS Spending
Retevmo (Selpercatinib) by Eli Lilly: FDA Orange Book core substance LOE 2039-04-10, 0 AB generics, $100.2M 2024 CMS Part D & Medicaid spend, and $22,598 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Eli Lilly |
| FDA Application & Pathway | N213246 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2039-04-10 |
| Last Listed Patent or Exclusivity Date | 2039-04-10 |
| Orange Book Patents (*PED Extensions) | 12 patents (6 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $100.2M |
| 2024 Medicare Part D Spend | $84.9M |
| 2024 Medicaid Spend | $15.3M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($22,598 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.